Ductal Carcinoma

Subscribe to Selected New Research on Ductal Carcinoma

1067 relevant articles (11 outcomes, 126 trials/studies) found for this Disease

Description: Malignant neoplasms involving the ductal systems of any of a number of organs, such as the MAMMARY GLANDS, the PANCREAS, the PROSTATE, or the LACRIMAL GLAND.

Also Known As:

Carcinoma, Ductal; Carcinomas, Ductal; Ductal Carcinomas

Relationship Network

Disease Context: Research Results

Neoplasms: 386513

Neoplasms by Histologic Type: 1

Glandular and Epithelial Neoplasms: 238

Carcinoma: 89295

Adenocarcinoma: 25769

Ductal Carcinoma: 1067

Pancreatic Ductal Carcinoma: 112

Breast Ductal Carcinoma: 71

Neoplasms, Ductal, Lobular, and Medullary

Ductal Carcinoma: 1067

Pancreatic Ductal Carcinoma: 112

Breast Ductal Carcinoma: 71

Related Diseases

1.	Carcinoma (Carcinomatosis)
2.	Neoplasms (Cancer)
3.	Noninfiltrating Intraductal Carcinoma (DCIS)
4.	Hyperplasia
5.	Syndrome
98 Diseases and 599 more articles analyzed in the Full Patient-Physician Summary Report, order at left...

Experts

1.	Ruibal, A: 6 articles (10/2001 - 06/2000)
2.	Tejerina, A: 5 articles (08/2001 - 06/2000)
3.	Schneider, J: 4 articles (08/2001 - 06/2000)
4.	Imoto, Shigeru: 3 articles (03/2008 - 01/2004)
5.	Hasebe, Takahiro: 3 articles (03/2008 - 01/2004)
6.	Arias, J I: 3 articles (10/2001 - 07/2000)
7.	Lapeña, G: 3 articles (08/2001 - 07/2000)
8.	del Río, M C: 3 articles (10/2000 - 06/2000)
9.	Arias, J: 3 articles (10/2000 - 06/2000)
10.	Rath, Gayatri: 2 articles (08/2008 - 01/2007)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Ductal Carcinoma:

1.	MucinsIBA 06/01/2002 - "In previous studies of the expression of MUC1 (membrane-bound type mucin) and MUC2 (intestinal type secretory mucin) in pancreatic tumours, invasive ductal carcinoma (IDC) usually showed MUC1+ and MUC2- expression, whereas intraductal papillary-mucinous tumour (IPMT) showed MUC1- and MUC2+ expression" 05/28/1992 - "Taking into consideration the relationship of breast neoplasia with recent knowledge obtained on the molecular structure and biosynthesis of the breast epithelial mucin, an epitope on this molecule detected by monoclonal antibody (MAb) BrE-3 was chosen as a marker to study the correlation of expression of the mucin and prognosis in infiltrating ductal carcinomas of the breast" 04/01/2005 - "One of these genes, the small breast epithelial mucin, is almost completely downregulated upon a first full-term pregnancy but is known to be expressed in more than 90% of invasive ductal carcinomas." 12/01/1995 - "They consist of densely eosinophilic protein or radiating, fibrillar ground substances, and they differ in appearance from the disorganized, flocculent mucin and the cellular debris found in some in situ ductal carcinomas" 01/01/1988 - "Circulating mucin was found in a 40-year-old woman with metastatic ductal carcinoma of the breast" Get all the results and reference details, order at left...
2.	Cadherins (E-Cadherin)IBA 05/01/2006 - "In this study, we examined the association between the expression of MUC1, MUC2, MUC5AC, and E-cadherin, and the pathological changes from normal pancreatic tissue to invasive ductal carcinoma(IDC)" 08/01/2004 - "METHODS: Immunohistochemical study for E-cadherin was performed on 64 cases of IMPC and 57 cases of invasive ductal carcinoma (IDC)" 02/01/2001 - "Prior studies have shown that E-cadherin protein expression is lost in lobular but not ductal carcinomas" 05/01/2008 - "METHODS: Using real-time polymerase chain reaction, the number of N-cadherin transcripts in normal breasts (n = 32) and infiltrating ductal carcinomas (n = 90) was assessed" 05/01/2008 - "Is N-cadherin expression important in ductal carcinoma?" Get all the results and reference details, order at left...
3.	Keratins (Keratin)IBA 04/30/1991 - "Other markers may be positive in both ACC and ductal carcinoma; these are not specific and only the percentage and distribution of positive cells are helpful for diagnosis (small clusters of keratin-positive cells in ACC "versus" most positive cells in ductal carcinoma)" 11/01/2005 - "AIMS: To study the expression of p63, cytokeratin (CK) 5 and CK8/18 in invasive ductal carcinomas and their relationship with BRCA1 and other pathological and immunohistochemical features of clinical significance" 10/01/1996 - "However, the role of wide-spectrum cytokeratin staining of HE-negative BMCs from patients with ductal carcinoma has not been as well determined and is the purpose of this study" 10/15/2007 - "Cytokeratin KRT8/18 expression differentiates distinct subtypes of grade 3 invasive ductal carcinoma of the breast." 03/10/2005 - "Cytokeratin-positive cell dissemination in patients with in situ ductal carcinoma of the breast." Get all the results and reference details, order at left...
4.	Carbon DioxideIBA 11/01/1997 - "OBJECTIVE: The aim of this study was to evaluate the clinical efficacy of contrast-enhanced sonography using carbon dioxide microbubbles to differentiate inflammatory pancreatic masses from ductal carcinomas of the pancreas" 11/01/1997 - "Inflammatory pancreatic masses: differentiation from ductal carcinomas with contrast-enhanced sonography using carbon dioxide microbubbles." Get all the results and reference details, order at left...
5.	Fluorouracil (Carac)FDA LinkGeneric 01/01/2002 - "We assessed the expression of TS in invasive ductal carcinoma (IDC) of the pancreas by immunostaining and evaluated its clinicopathological significance, especially its implications regarding the efficacy of chemotherapy with 5-FU or its derivatives" 01/01/2001 - "We report herein the case of a 40-year-old man with grade II invasive ductal carcinoma of the breast (pT1, pN0, M0: stage I) in whom a recurrence developed shortly after completion of a 2-year course of tamoxifen and 5-fluorouracil therapy following a mastectomy" 01/01/1989 - "Three months after onset of symptoms, infiltrating ductal carcinoma of the breast, metastatic to liver and lymph nodes, was diagnosed and treated briefly with cyclophosphamide, methotrexate, and 5-flourouracil (5FU)" 08/01/1989 - "A 57-year-old woman developed severe tumor lysis syndrome characterized by acute hyperuricemic nephropathy, hyperphosphatemia, hyperkalemia, and hypocalcemia after therapy with cyclophosphamide, methotrexate, and 5-fluorouracil for metastatic infiltrating ductal carcinoma of the breast involving the chest wall, lungs, pleurae, and liver" 06/01/1998 - "METHODS: From May 1994 to February 1995, 12 consecutive patients with biopsy-proven advanced ductal carcinoma of the exocrine pancreas were given intra-arterial infusions consisting of Mitoxantrone, 5-FU + folinic acid, and Cisplatin via a transfemorally placed catheter in the celiac axis" Get all the results and reference details, order at left...
6.	Keratin-5 (Keratin 5)IBA 09/01/2000 - "In contrast, neoplastic epithelial cells in atypical ductal and lobular hyperplasias (ADH and ALH) lacked such an expression, whereas in ductal in-situ carcinomas (DCIS) and in infiltrating ductal carcinomas 3.7% and 7.7%, of the cases respectively, showed positive immunostaining for CK 5/6. CONCLUSIONS: Immunophenotyping of keratin 5/6 expression can be helpful in the diagnosis of atypical hyperplasias and in-situ carcinomas of the breast" 01/01/2007 - "P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ." Get all the results and reference details, order at left...
7.	prothymosin alphaIBA 01/01/1993 - "In 71 patients with classic invasive ductal carcinomas, levels of prothymosin alpha (PT alpha), as assayed by a radioimmunoassay that detects thymosin alpha 1 (the NH2-terminal fragment of PT alpha), were significantly greater in tumour samples than in normal breast tissue" Get all the results and reference details, order at left...
8.	thymalfasinIBA 01/01/1993 - "In 71 patients with classic invasive ductal carcinomas, levels of prothymosin alpha (PT alpha), as assayed by a radioimmunoassay that detects thymosin alpha 1 (the NH2-terminal fragment of PT alpha), were significantly greater in tumour samples than in normal breast tissue" Get all the results and reference details, order at left...
9.	Estrogens (Estrogen)FDA Link 01/01/2007 - "Altered p-JAK1 expression is associated with estrogen receptor status in breast infiltrating ductal carcinoma." 06/15/2006 - "STAT3 ser727 phosphorylation and its association with negative estrogen receptor status in breast infiltrating ductal carcinoma." 01/01/2006 - "In addition, 17beta-HSD type 1 coexpression is significantly correlated with estrogen receptor status in invasive ductal carcinoma cases" 12/01/2004 - "Nine of 12 (75%) p16-negative ductal carcinomas were estrogen receptor (ER) positive" 01/01/2004 - "Histological examination of biopsy specimens revealed highly differentiated estrogen receptor-positive ductal carcinomas" Get all the results and reference details, order at left...
10.	ParaffinIBA 08/01/2004 - "METHODS: Ninety two cases of paraffin-embedded lesional breast tissue, 30 cases of frozen samples, cell cultures of hyperplastic ductal cells and 2 invasive ductal carcinoma cell lines (T47D and MCF-7) were used for this study" 08/01/1999 - "Results were compared to that obtained on paraffin sections and in a series (n=55) of grade 3 ductal carcinomas" 05/01/1995 - "To assess the practical prognostic value of pS2, we evaluated its expression by immunohistochemistry in paraffin-embedded tissue from 942 previously untreated invasive ductal carcinomas (IDC) resected in our center between 1980 and 1986" 06/01/1994 - "Paraffin sections from 137 cases of invasive ductal carcinoma of the breast were investigated" 05/01/2000 - "Studies were performed using paraffin-embedded tissue from 13 ductal carcinomas, 23 invasive ductal carcinomas, five normal breasts and 25 bone metastases" Get all the results and reference details, order at left...
407 Drugs and Important Bio-Agents and 888 more articles analyzed in the Full Patient-Physician Summary Report, order at left...

Therapies and Procedures

1.	Adjuvant Chemotherapy 03/01/1999 - "This study was designed to assess the significance of p53 and WAF/1-p21 expression in the prognosis of patients and the efficacy of adjuvant chemotherapy for resectable invasive ductal carcinoma (IDC) of the pancreas" 09/01/1998 - "The present study assessed the implication of p53 expression in the prognosis of patients and the efficacy of adjuvant chemotherapy for resectable invasive ductal carcinoma (IDC) of the pancreas" 07/01/2003 - "These results suggested that assessment of histological heterogeneity of invasive ductal carcinoma could serve as independent potent prognostic factor for node-negative invasive ductal carcinoma of the breast, and this method might be useful to decide indication of postoperative adjuvant chemotherapy." 01/01/1986 - "The mortality among patients with stage I infiltrating ductal carcinoma not given adjuvant therapy suggests the need for proper selection of patients in this group who should receive adjuvant chemotherapy because they are at increased risk." 01/01/2006 - "CASE PRESENTATION: A 61-year-old postmenopausal woman who had undergone surgery and treated with adjuvant chemotherapy for infiltrating ductal carcinoma of the breast five years ago, presented with bloody vaginal discharge, fatigue, weight loss, and low grade fevers at night for two months" Get all the results and reference details, order at left...
2.	Drug Therapy (Chemotherapy) 02/26/2008 - "This study aims to compare the outcome of lobular vs ductal carcinomas after neoadjuvant chemotherapy" 02/26/2008 - "Clinical response to primary chemotherapy was significantly worse for lobular than for ductal carcinomas (47 vs 60%; P=0.04), but only histological grade remained predictive in multivariate analysis" 09/01/2006 - "PATIENTS AND METHODS: Seventeen patients with large or locally advanced invasive ductal carcinomas of the breast were imaged using DCE-MRI and (18)F-FDG-PET prior to therapy and 20 days after the first cycle of chemotherapy" 08/01/2006 - "MATERIALS AND METHODS: Serial (1)H MR spectra were recorded both before and after the completion of chemotherapy in 33 LABC patients (with infiltrating ductal carcinoma (IDC)) at 1.5T" 07/01/2006 - "BACKGROUND: Grade-III invasive ductal carcinomas of no special type (IDCs-NST) constitute a heterogeneous group of tumours with different clinical behaviour and response to chemotherapy" Get all the results and reference details, order at left...
3.	Simple Mastectomy 03/01/2005 - "An 83-year-old woman underwent simple mastectomy and sentinel lymph node biopsy (SLNB) for infiltrating ductal carcinoma" 09/01/2004 - "We presented a case of a 79-year-old woman with this syndrome and a small invasive ductal carcinoma [pT1aN0(sn)M0], whose symptoms improved 3 months following her simple mastectomy without any adjuvant therapy" 06/01/2002 - "Surgical management evolved from radical and modified radical mastectomy to simple mastectomy or lumpectomy during the study period, during which time 1 patient died of previous ordinary ductal carcinoma of the contralateral breast, and 7 died of unrelated disease" 01/01/1996 - "The unique case of a 51-year-old woman who developed a solitary brain metastasis as the first site of systemic disease 11 months after a total mastectomy for an undifferentiated infiltrating ductal carcinoma of her right breast is described" 06/15/1980 - "These findings suggested that any therapeutic procedure for either invasive or non-invasive ductal carcinoma that does not include total mastectomy may leave behind foci of cancer, which are a threat to the patient." Get all the results and reference details, order at left...
4.	Microbubbles 11/01/1997 - "OBJECTIVE: The aim of this study was to evaluate the clinical efficacy of contrast-enhanced sonography using carbon dioxide microbubbles to differentiate inflammatory pancreatic masses from ductal carcinomas of the pancreas" 11/01/1997 - "Inflammatory pancreatic masses: differentiation from ductal carcinomas with contrast-enhanced sonography using carbon dioxide microbubbles." Get all the results and reference details, order at left...
5.	Mastectomy (Mammectomy) 07/01/2007 - "50 patients who underwent FNAC and mastectomy for infiltrating ductal carcinoma were included in the study" 06/15/2006 - "The purpose of this study was to compare the conversion rate from BCT to mastectomy among patients with lobular (ILC) and ductal carcinoma (IDC), and to compare the number of resections needed to obtain negative margins" 03/01/2003 - "STUDY DESIGN: We studied 35 women who underwent mastectomy following an FNA diagnosis of infiltrating ductal carcinoma" 07/02/1994 - "The recent results of the B-17 NSBAP trial also conclude that the radiosurgical conservative treatment, for limited in situ ductal carcinoma, is a reasonable alternative to mastectomy." 06/01/2008 - "We report synchronous bilateral Paget disease with infiltrative ductal carcinoma in a 74-year-old man who underwent bilateral mastectomy." Get all the results and reference details, order at left...
34 Therapies and Procedures and 226 more articles analyzed in the Full Patient-Physician Summary Report, order at left...

Patient-Physician
Research Summary Report
on Ductal Carcinoma

*WARNING* This specific disease subtype has a relatively small number of significant evidence outcomes. You may proceed to order anyway, or go back to the search field and enter a more general type of the target illness. Once your report has been ordered, however, we can't refund the purchase.

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 11 Outcomes
Top 200 Key Medications
Top 34 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF for "Psoriasis" >>

Price:

$24.00 & Delivery via PDF download,
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>